Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830565 | 0.81 | MEN1 (0.56) | MEN1POLBKMT2ACYP1A2ALDH1A1 | |
| SCHEMBL12125206 | 0.81 | MEN1 (0.50) | MEN1POLBKMT2ACYP1A2ALDH1A1 | |
| SCHEMBL21148619 | 0.80 | PIK3CD (0.56) | MEN1POLBKMT2APIK3CDCYP1A2 | |
| SCHEMBL13133175 | 0.77 | MEN1 (0.52) | MEN1POLBKMT2ACYP1A2ALDH1A1 | |
| SCHEMBL21889830 | 0.77 | BLM (0.39) | MEN1POLBKMT2APIK3CDCYP1A2 | |
| SCHEMBL31066751 | 0.77 | MEN1 (0.52) | MEN1POLBKMT2ACYP1A2ALDH1A1 | |
| SCHEMBL18357965 | 0.77 | MEN1 (0.52) | MEN1POLBKMT2ACYP1A2ALDH1A1 | |
| SCHEMBL19554732 | 0.77 | MEN1 (0.46) | MEN1POLBKMT2ACYP1A2ALDH1A1 | |
| SCHEMBL173217 | 0.76 | CYP1A2 (0.40) | MEN1POLBKMT2APIK3CDCYP1A2 | |
| SCHEMBL12846704 | 0.76 | PIK3CD (0.61) | PIK3CDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214370-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214370-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | MEN1 3670/4885POLB 963/4885KMT2A 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.